StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Investment analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Capital downgraded shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Stock Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.35 on Wednesday. The firm has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.69. The company has a market cap of $2.20 million, a P/E ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $4.00.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.